Bicycle therapeutics to present new translational data for bt1718 and preclinical data for other bicycle® toxin conjugates at aacr-nci-eortc 2019

Bicycle therapeutics plc announced that new translational data for bt1718 and preclinical data for bt5528 and bt8009 will be presented during poster sessions at the aacr-nci-eortc international conference on molecular targets and cancer therapeutics on october 26-30, 2019 in boston, ma. new translational data will be presented for bt1718, the company’s lead bicycle® toxin conjugate (btc) product candidate, which define enrollment criteria for identifying expansion cohorts in the phase iia part of the ongoing phase i/iia trial with bt1718. the phase i/iia study, sponsored by cancer research uk, is currently in phase i dose escalation in patients with advanced solid tumors who have not been pre-selected for mt1-mmp status. once a recommended once-weekly phase ii dose is established, the company expects to initiate the phase iia expansion, which will include patients determined to be mt1-mmp-postive based on a prespecified tumor membrane h-score. initially, patients will be enrolled into two expansion cohorts, one in squamous lung cancer and the other in an all-comers “basket” cohort. depending on results from these first two cohorts, additional cohorts may be initiated. additional preclinical data will also be presented for bicycle’s other btc programs, bt5528 and bt8009, which show target-dependent anti-tumor activity across a range of epha2-expressing and nectin-4-expressing cancer models, respectively.
BCYC Ratings Summary
BCYC Quant Ranking